Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q4 2010

Published by: Global Markets Direct

Published: Dec. 27, 2010 - 27 Pages


Table of Contents

Introduction
Global Markets Direct Report Coverage
Systemic Juvenile Idiopathic Arthritis (SJIA) Overview
Therapeutics Development
An Overview of Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA)
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Development by Companies
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics under Investigation by Universities/Institutes
Companies Involved in Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Development
XOMA Ltd.
Italfarmaco S.p.A.
Txcell SA
Universities/Institutes Involved in Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Development
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles - Universities/Institutes
Anakinra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Systemic Juvenile Idiopathic Arthritis (SJIA) - Featured News
Oct 18, 2010: Roche Submits ACTEMRA/RoACTEMRA Supplemental Marketing Authorizations In US And Europe For Treatment Of Systemic Juvenile Idiopathic Arthritis
Jun 15, 2010: TxCell Successfully Completes Preclinical Development of TX-RAD in Inflammatory Arthritis
Nov 20, 2009: Roche Announces Phase III Clinical Study Results Of ACTEMRA In Children With Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), 2010
Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis, 2010
XOMA Ltd., 2010
Italfarmaco S.p.A., 2010
Txcell SA, 2010
Assessment by Monotherapy Products, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
List of Figures
Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), 2010
Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Assessment by Monotherapy Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010

Abstract

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Systemic Juvenile Idiopathic Arthritis Pipeline Review, Q4 2010”, provides an overview of the Systemic Juvenile Idiopathic Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Juvenile Idiopathic Arthritis . “Systemic Juvenile Idiopathic Arthritis -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Systemic Juvenile Idiopathic Arthritis   .
  • A review of the Systemic Juvenile Idiopathic Arthritis    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Systemic Juvenile Idiopathic Arthritis    pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • A snapshot of the global therapeutic scenario for Systemic Juvenile Idiopathic Arthritis   .
  • A review of the Systemic Juvenile Idiopathic Arthritis    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Systemic Juvenile Idiopathic Arthritis    pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.